Product details

μCaler EMS Panel v1.0

Catalog Number:

#1101501
#1101502

μCaler EMS Panel v1.0 (Early Methylation for Screening) covers methylation gene sites related to nine major high-incidence cancers, including selected sites approved by the NMPA and FDA, as well as those reported in literature and patents. It encompasses nine types of cancers, including lung cancer, colorectal cancer, gastric cancer, liver cancer, breast cancer, carcinoma cancer, prostate cancer, cervical cancer, and ovarian cancer, involving 76 methylated candidate genes associated with carcinog enesis and tumor suppression, with over 2,000 CpG sites. The probe design covers approximately 20 Kb of the human genome, providing comprehensive and accurate support for methylation early screening.

Request Quote

Product details
Kit Content
FAQ
Ordering Information
Resources

Gene list

Species of Cancer	Biomarker
Lung Cancer	SCT、HOXA7、RASSF1、SHOX2、PTGER4
Colorectal Carcinoma	NDRG4、BCAT1、Septin9、BMP3、TFPI2、SDC2、SFRP2
Gastric Cancer	Septin9、RNF180、TCF4、RPRM、SDC2、TERT
Liver Cancer	SCN4B、BDH1、HOXA10、PLAC8、BMPR1A、TEPP、SPACA6、MIXL1、TSC22D1
Breast Cancer	CDO1、PITX2、GSTP1、GP5、APC
Carcinoma Cancer	SOX1、GALR1、DMRTA2、EVX2、SOX17、DCHS2、TWIST1、TBX5、HOXA11、SIM2、LHX2
Prostatic Cancer	CCND2、CDH1、MCAM、PENK、PITX2、PTGS2、RARB、LINC02028、SLCO3A1、HES5、TPM4、FHAD1、SOX1-OT、IGFBP3、ZNF154、FEZF2、APC
Cervical Cancer	SOX1、PAX1、JAM3、TAFA4、ASTN1、DLX1、ITGA4、RXFP3、SOX17
Ovarian Cancer	PCDHB18P、CDO1、HOXA9、LYPD5、CDH13、FOXD3、ZNF671、HOXA11、FBXO32、OPCML、BLACAT1、LRRC41、GNE、FAIM2、CAPN2、SIM2

Product Features

Multi-Cancer Detection: Covers CpG sites of multiple genes for 9 major cancer types in a single detection
Sample Compatibility: Suitable for gDNA, cfDNA, and various level of FFPE samples.
Accurate Quantification: Achieves precise quantification of methylation levels in tested samples.
Efficient Capture: Combines with μCaler Total Solution for Methylation to ensure uniform data quality, higher capture eff iciency and stability
High Reliability: Utilizes exclusive patented probe design to comprehensively detect methylation status, providing reliable results.
Stable Delivery: In-house nucleic acid synthesis manufacturing ensures on-hand delivery and guarantees the stability of the delivery chain.
Flexible Customization: Customizes panels containing different genes and scales of CpG sites for testing specific single/ multiple cancer types.

Performance

Compatible with different sample types

Figure 1. Capture performance of μCaler EMS Panel v1.0 applied to gDNA and cfDNA samples. A. gDNA ; B. cfDNA; C. Fold 80 base penalty；D. CpG total depth of target regions (deduplicated). Samples were used to prepare pre-library using the NadPrep Methyl Library Preparation Module, with gDNA undergoing conversion using NadPrep DNA Methyl Bisulfite Conversion Module (BS), and cfDNA undergoing conversion using both BS and enzymatic (EM) methods. 500 ng/pre-library was inputted, and hybrid capture was performed using μCaler Hybrid Capture Reagents v2 and μCaler EMS Panel v1.0.
Note: gDNA samples refer to Human Genomic DNA standard (Promega, G1471), with an input of 50 ng; cfDNA samples refer to plasma cfDNA, with an input of 20 ng.

Figure 2. Capture performance of μCaler EMS Panel v1.0 applied to different grades of FFPE samples. A. Capture performance; B. Fold 80 base penalty. Pre-library were prepared using the NadPrep Methyl Library Preparation Module, followed by conversion using the NadPrep DNA Methyl Bisulfite Conversion Module. 500 ng of pre-library was inputted, and hybrid capture was performed using μCaler Hybrid Capture Reagents v2 and μCaler EMS Panel v1.0.
Note: FFPE samples were clinical lung cancer samples, input 50 ng. Sample grading criteria: FFPE B: Main bands around 15 Kb with moderate smearing; FFPE C: Bands primarily distributed between 200-2500 bp, appearing diffuse; FFPE D: Bands mainly distributed between 100-1000 bp, appearing diffuse.

Clinical Sample Detection Performance

Colorectal Cancer

Figure 3. Capture performance of μCaler EMS Panel v1.0 applied to clinical colorectal cancer and peritumoral tissue samples. A. On target & Mappability; B. CpG coverage; C. Fold 80 base penalty.
Note: CRC: Colorectal Cancer。

Figure 4. Methylation level detection of μCaler EMS Panel v1.0 applied to clinical colorectal cancer and peritumoral tissue samples. A. CpG methylation level in paired colorectal cancer samples; B. CpG methylation level of colorectal cancer candidate biomarkers in real samples.
Note: CRC: Colorectal Cancer; Pt: Peritumoral tissue.

Ovarian Cancer

Figure 5. The methylation level detection of μCaler EMS Panel v1.0 applied to clinical ovarian cancer and peritumoral tissue. A. CpG methylation level in paired ovarian cancer samples; B. CpG methylation level of ovarian cancer candidate biomarkers in real samples.
Note: OVCA: Ovarian Cancer; Pt: Peritumoral tissue.

Lung Cancer

Figure 6. The methylation level detection of μCaler EMS Panel v1.0 applied to clinical lung cancer tissue. A. CpG methylation level in lung cancer samples; B. CpG depth in lung cancer samples; C. CpG me thylation level of lung cancer candidate biomarkers in clinical samples.
Note: LC: Lung Cancer。

For research use only. Not for use in diagnostic procedures.

Catalog	Color Of Tube Cap	Product	Volume	Package/Storage
1101502		μCaler EMS Panel v1.0, 16 rxn	40 μL	-25~-15℃
1101501		μCaler EMS Panel v1.0, 96 rxn	210 μL	-20~-15℃